We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




First-Ever Medical Technology Regrows Nerves and Stops Amputations in Diabetic Patients

By HospiMedica International staff writers
Posted on 06 Oct 2025

Chronic wounds are among the most devastating and costly complications for diabetic and trauma patients, often leading to severe infections, tissue death, and amputations. More...

Despite the global wound care market exceeding USD 22 billion, existing treatments such as wound vacs, grafts, and antimicrobial creams only manage symptoms rather than addressing underlying nerve and circulation damage. Now, a new regenerative medical technology can restore nerve function, heal tissue, and prevent amputations in patients once deemed untreatable.

Developed by Rapid Nexus (Brea, CA, USA), the patented device is the first medical technology proven to regenerate nerves and reverse chronic wounds. Unlike other products that just protect the tissue, this technology, adapted to treat advanced wounds, uses a top-down approach that rebuilds the surrounding tissue and then works its way back into the bed of the wound.

It works by targeting the root cause of tissue death — damaged nerve and vascular networks — restoring blood flow and tissue vitality from within. The approach goes beyond surface healing by combining nerve regeneration and improved circulation in a single treatment system, making it the first of its kind to actively repair rather than manage chronic wounds.

In a 2018 feasibility study, every patient previously diagnosed for amputation and treated with the technology successfully avoided limb loss. One case involved a 32-year-old diabetic mother whose leg had begun to turn necrotic; after treatment, nerve regeneration and restored blood flow allowed her to walk again.

The most recent peer-reviewed study, scheduled for publication this fall, reports dozens of biomarkers working simultaneously to trigger nerve and vascular regeneration — an outcome described as unprecedented in wound healing research. The device is currently completing FDA review and has entered clinical trials with commercial rollout expected by late 2025, thus expanding its use to hospitals, home care, and underserved regions worldwide.

“We could apply this healing approach to the whole body — and prevent countless amputations that were once seen as inevitable,” said Dr. Margaret Kalmeta, founder of Rapid Nexus. “This is about restoring human dignity, one limb at a time.”

Related Links:
Rapid Nexus


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Multi-Chamber Washer-Disinfector
WD 390
Tourniquet System
heidi– mein Tourniquet
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Initial PSMA PET/CT scan showing (from top to bottom) positive lesions in T11, an aortocaval node, a right common iliac node, a right internal iliac node, and the prostate bed. The T11 lesion was identified as a hemangioma on a subsequent MRI. MRI indicates magnetic resonance imaging; PET/CT, positron-emission tomography/computed tomography; PSMA, prostate-specific membrane antigen. (Kishan AU, Zekster Y, Singer AE, et al. CA: A Cancer Journal for Clinicians. 2026. doi:10.3322/caac.70111)

PSMA PET/CT Imaging Guides Treatment Selection in Recurrent Prostate Cancer

Prostate cancer can return after surgery, sometimes appearing in different locations over time. A rising prostate-specific antigen (PSA) level may be the first sign of recurrence, while microscopic disease... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: WHX returns to Dubai Exhibition Centre, Expo City, and Dubai World Trade Centre from 5–28 January 2027 (Photo courtesy of World Health Expo)

World Health Expo to Showcase Trillion-Dollar Growth Across Pharma, Biotech, Longevity and Wellness at 2027 Edition

World Health Expo (WHX) expands with the new Pharma, Biotech, Longevity and Wellness industry sectors More than 235,000 professional visits, over 4,200 exhibitors and representatives from over... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.